Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

Summary

This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician's assessment that the potential benefits outweigh the potential risks, with appropriate clinical monitoring for safety and tolerability.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications